Evidence map›Paper›PMID 24935440›Full record

ArticleProteins2014

Cytotoxicity of the Vibrio vulnificus MARTX toxin effector DUF5 is linked to the C2A subdomain.

Irena Antic, Marco Biancucci, Karla J F Satchell

Open access · greenAbstract readComparative Study
In one paragraph

Article in Proteins, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. RAS degraders: The new frontier for RAS-driven cancers.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  3. TheToxins · 2023
    Article
  4. Article
  5. Article
  6. Actin Cross-Linking Effector Domain of theInfection and immunity · 2022
    Article
  7. Article
  8. Article
  9. TheFrontiers in microbiology · 2020
    Article
  10. Article
  11. Emerging microbes & infections · 2019
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. VopE, aFrontiers in cellular and infection microbiology · 2017
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Irena AnticDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, 60611.
Marco Biancucci
Karla J F Satchell
Northwestern University · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Molecular mechanism of V. vulnificus MARTX toxin in pathogenesis and food safetyR01AI092825 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SATCHELL, KARLA J F · 2011 to 2021
$4.1M
Genetic and biochemical study ov V. cholerase RTX toxinR01AI051490 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SATCHELL, KARLA J F · 2003 to 2012
$3.3M
Vibrio MARTX toxin effectors in signaling and pathogenesisR37AI092825 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Karla J F Satchell · 2022 to 2026
$2.5M
Function of Vibrio vulnificus MARTX toxin during early gut infectionR01AI098369 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SATCHELL, KARLA J F · 2012 to 2016
$1.3M
NCI NIH HHS P30 CA060553NIAID NIH HHS R01 AI051490NIAID NIH HHS R01AI051490NIAID NIH HHS R01 AI092825NIAID NIH HHS R01AI092825NIAID NIH HHS R01 AI098369NIAID NIH HHS R37 AI092825PHS HHS R01098369
6 · The paper itself

Abstract

The multifunctional-autoprocessing repeats-in-toxin (MARTX) toxins are bacterial protein toxins that serve as delivery platforms for cytotoxic effector domains. The domain of unknown function in position 5 (DUF5) effector domain is present in at least six different species' MARTX toxins and as a hypothetical protein in Photorhabdus spp. Its presence increases the potency of the Vibrio vulnificus MARTX toxin in mouse virulence studies, indicating DUF5 directly contributes to pathogenesis. In this work, DUF5 is shown to be cytotoxic when transiently expressed in HeLa cells. DUF5 localized to the plasma membrane dependent upon its C1 domain and the cells become rounded dependent upon its C2 domain. Both full-length DUF5 and the C2 domain caused growth inhibition when expressed in Saccharomyces cerevisiae. A structural model of DUF5 was generated based on the structure of Pasteurella multocida toxin facilitating localization of the cytotoxic activity to a 186 amino acid subdomain termed C2A. Within this subdomain, an alanine scanning mutagenesis revealed aspartate-3721 and arginine-3841 as residues critical for cytotoxicity. These residues were also essential for HeLa cell intoxication when purified DUF5 fused to anthrax toxin lethal factor was delivered cytosolically. Thermal shift experiments indicated that these conserved residues are important to maintain protein structure, rather than for catalysis. The Aeromonas hydrophila MARTX toxin DUF5(Ah) domain was also cytotoxic, while the weakly conserved C1-C2 domains from P. multocida toxin were not. Overall, this study is the first demonstration that DUF5 as found in MARTX toxins has cytotoxic activity that depends on conserved residues in the C2A subdomain.

Indexed as

Models, MolecularAeromonas hydrophilaAntibiotics, AntineoplasticBacterial ToxinsCell ShapeFemaleHeLa CellsHumansMutant ProteinsPasteurella multocidaPeptide FragmentsPhotorhabdusProtein ConformationProtein Interaction Domains and MotifsProtein StabilityProtein TransportAntibiotics, AntineoplasticBacterial ToxinsMutant ProteinsPeptide FragmentsRecombinant Fusion ProteinsRecombinant Proteinscytotoxineffector domainsMARTXVibrio vulnificusyeast screen

Identifiers

PMID24935440
PMCPMC4177264
OpenAlexW1533109021

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.